Sanford (SAN) has announced a solid result for FY22 and provided updates on its key strategic initiatives, but no FY23 guidance was included in this result; the outlook includes key positives from strong price and demand, as well as the commissioning of the Bioactives plant and a net benefit from a weaker NZD
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.